Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSeeking Alpha· November 25, 2025

Blue Bird maintains $1.5B revenue and 14.7% EBITDA margin guidance for 2026 while signaling strong EV and chassis expansion

View original at seekingalpha.com
Blue Bird maintains $1.5B revenue and 14.7% EBITDA margin guidance for 2026 while signaling strong EV and chassis expansion Earnings Call Insights: Blue Bird Corporation (BLBD) Q4 2025 MANAGEMENT VIEW * John Wyskiel, President and CEO, stated that "Blue Bird beat guidance on all metrics and delivered a record year," de…
Opening lines of the source · Seeking Alpha · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Commercial chassis prototypes are in testing and the product is well received by customers who have looked at it

    80% confidence
  • Gross margin for Q4 was 21% or 4.1 percentage points higher than last year due to sustained operational performance and pricing overtaking inflationary costs including tariff effects

    80% confidence
  • Blue Bird feels very good about the 750 guidance of EV and there is some upside potential up to 1,000 units in fiscal 2026

    80% confidence
  • Blue Bird's track record and dominance in alternative powered vehicles continues with stable EV demand despite tariff pricing uncertainty and EPA funding, and the outlook in this area remains strong

    80% confidence
  • Outside of the federal side, there is real demand at the state level for EV buses

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com